The postoperative analgesic effect of single-shot retrolaminar block for breast cancer surgery: a double-masked, placebo-controlled, randomized clinical trial

The postoperative analgesic effect of single-shot retrolaminar block for breast cancer surgery: a double-masked, placebo-controlled, randomized clinical trial - The postoperative analgesic effect of single-shot retrolaminar block for breast cancer surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019982

Enrollment

150

Registered

2015-11-29

Start date

2014-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer surgery

Interventions

Single-shot retrolaminar block with total 30mL of 0.5% ropivacaine Single-shot retrolaminar block with total 30mL of normal saline

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. ASA physical status 1 - 2 2. Under general anesthesia 3. Breast cancer surgery with axillary lymph node dissection

Exclusion criteria

Exclusion criteria: 1. Estimated glomerular filtration rate < 60 mL / min / 1.73 * square meter 2. NYHA classification > II 3. Hugh-Jones classification > II 3. Active phase peptic ulcer 4. BMI < 15 or BMI >= 35 5. Skin lesion at a block site 6. Allergies to local anesthetics, pentazocine or NSAIDs 7. Past history of severe postoperative nausea and vomiting

Design outcomes

Primary

Measure	Time frame
The number of patients who need analgesics within 12 hours after surgery	—

Secondary

Measure	Time frame
1. The number of patients who need antiemetics within 12 hours after surgery 2. Numerical pain rating scores within 3 hours after surgery	—

Countries

Japan

Contacts

Public ContactMamoru Murakami

Tohoku Kosai Hospital Department of anesthesiology

masuiker@gmail.com+08-22-227-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026